By Joe Gorelick, MSN, FNP-C How many patients do you see with contact dermatitis? Negative patch testing results can be so frustrating and perhaps this year’s Allergen of the Year—sulfites–could be the culprit. Sulfites, commonly used preservatives in consumer...
A $3.2 million grant from the NIH will support the creation of Melanoma Resistance Evolution Atlas (MREA). Ultimately, researchers hope to develop novel approaches to prevention and treatment of resistant melanomas. Led by Dr. Roger Lo, professor of medicine and...
By Joe Gorelick, MSN, FNP-C A 25-bill legislative package from Rhode Island legislators aimed at improving health care access and affordability in the Ocean State relies heavily on expansion of the primary care workforce, particularly NPs and PAs. RI Senate Health...
The FDA has approved a new botulinum toxin formulation for aesthetic use in the US. Letybo from Hugel America, Inc., a division of Hugel Inc., is approved to treat moderate-to-severe glabellar (frown) lines in adults. Letybo (letibotulinumtoxinA-wlbg) is expected to...
Bimzelx® (bimekizumab-bkzx) from UCB is now under FDA review for a total of four potential new indications. Supplemental biologics license applications (sBLA) were submitted in February for three spondyloarthritides indications: psoriatic arthritis (PsA),...
As the rate of growth of nurse practitioners (NPs) and physician assistants (PAs) in the US continues to rise rapidly, research shows that the share of healthcare visits provided by NPs and PAs has increased by 11% since 2013. According to the latest data, NPs and PAs...